There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on TherapeuticsMD (NYSE MKT:TXMD) and Eli Lilly & Co (NYSE:LLY) with bullish sentiments.
TherapeuticsMD (TXMD)
In a report released yesterday, William Tanner from Cantor Fitzgerald reiterated a Buy rating on TherapeuticsMD, with a price target of $27. The company’s shares closed yesterday at $6.62.
Tanner noted:
“: We reiterate the Overweight rating and $27 PT for TXMD stock. If the FDA approves TX-001 on time, we believe 2018 will be the most important year in the company’s history with FDA approval of two drugs and the launch of one. As the company executes on the business plan, we believe questions as to whether the company will become a meaningful player in women’s health will dissipate.”
According to TipRanks.com, Tanner is a 3-star analyst with an average return of 2.7% and a 50.0% success rate. Tanner covers the Healthcare sector, focusing on stocks such as Supernus Pharmaceuticals, Intra-Cellular Therapies, and Evofem Biosciences Inc.
Currently, the analyst consensus on TherapeuticsMD is a Strong Buy with an average price target of $20.33, which is a 207.1% upside from current levels. In a report issued on September 26, Oppenheimer also assigned a Buy rating to the stock with a $14 price target.
.
See today’s analyst top recommended stocks >>
Eli Lilly & Co (LLY)
In a report released yesterday, Louise Chen from Cantor Fitzgerald maintained a Buy rating on Eli Lilly & Co, with a price target of $110. The company’s shares closed yesterday at $106.69, close to its 52-week high of $107.84.
Chen wrote:
“The growth prospects for LLY’s key drugs — Verzenio — as well as its pipeline assets, especially in pain, are underappreciated, in our view. Valuation Summary We use a blend of DCF and EV/EBITDA analysis to arrive at our 12-month PT of $110. Our price target is currently under review. The Disclosure Section may be found on pages 3 – 4.Valuation We use a blend of DCF and EV/EBITDA analysis to arrive at our 12-month PT of $110.”
According to TipRanks.com, Chen is a 1-star analyst with an average return of 0.0% and a 38.4% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Aridis Pharmaceuticals Inc, and Melinta Therapeutics Inc.
Currently, the analyst consensus on Eli Lilly & Co is a Moderate Buy with an average price target of $102.20, a -4.2% downside from current levels. In a report issued on September 18, Barclays also maintained a Buy rating on the stock with a $112 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
